Should I buy or sell PMV Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMVP shares. View PMVP analyst ratings or view top-rated stocks .

What is PMV Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12-month price targets for PMV Pharmaceuticals' shares. Their PMVP share price targets range from $5.00 to $7.00. On average, they anticipate the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 252.0% from the stock's current price. View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts .

How have PMVP shares performed in 2024?

PMV Pharmaceuticals' stock was trading at $3.10 at the beginning of the year. Since then, PMVP shares have decreased by 48.1% and is now trading at $1.61. View the best growth stocks for 2024 here .

When is PMV Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PMVP earnings forecast .

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its earnings results on Thursday, February, 29th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08.

What ETF holds PMV Pharmaceuticals' stock?

IQ Chaikin U.S. Small Cap ETF holds 85,735 shares of PMVP stock, representing 0.26% of its portfolio.

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL) , Arista Networks (ANET) , Apollo Medical (AMEH) , Advanced Micro Devices (AMD) , Ambarella (AMBA) , Alexion Pharmaceuticals (ALXN) , Akoustis Technologies (AKTS) , Agios Pharmaceuticals (AGIO) , Admiral Group (ADM) and Adobe (ADBE) .

When did PMV Pharmaceuticals IPO?

PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free PMVP Stock Alerts

$1.61

-0.01 (-0.62%)

(As of 04:21 PM ET)

Compare

Today's Range: $1.58
▼
$1.65
50-Day Range: $1.51
▼
$1.93
52-Week Range: $1.18
▼
$9.72

Volume: 479,633 shs
Average Volume: 547,683 shs
Market Capitalization: $82.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Get PMV Pharmaceuticals alerts:

PMV Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 252.0% Upside
$5.67 Price Target
Short Interest: Bearish
6.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.53
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.44) to ($1.48) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

663rd out of 911 stocks

Pharmaceutical Preparations Industry

288th out of 412 stocks

3.5

Analyst's Opinion

Consensus Rating
PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
PMV Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.40% of the float of PMV Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
PMV Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in PMV Pharmaceuticals has recently increased by 15.04%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
PMV Pharmaceuticals does not currently pay a dividend.
Dividend Growth
PMV Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PMVP.

2.5

News and Social Media Coverage

News Sentiment
PMV Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for PMVP on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
3 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.60% of the stock of PMV Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PMV Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PMV Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PMV Pharmaceuticals has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About PMV Pharmaceuticals Stock (NASDAQ:PMVP)

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

PMVP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PMVP Stock News Headlines

April 19, 2024 | finance.yahoo.com

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

April 18, 2024 | msn.com

PMV Pharmaceuticals (PMVP) Price Target Increased by 45.83% to 8.93

April 19, 2024 | Behind the Markets (Ad)

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

April 14, 2024 | americanbankingnews.com

PMV Pharmaceuticals (NASDAQ:PMVP) Now Covered by Jefferies Financial Group

March 27, 2024 | globenewswire.com

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

March 18, 2024 | finance.yahoo.com

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

March 18, 2024 | globenewswire.com

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

March 16, 2024 | finance.yahoo.com

PMVP Apr 2024 5.000 call

April 19, 2024 | Behind the Markets (Ad)

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

March 3, 2024 | finanznachrichten.de

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

March 1, 2024 | markets.businessinsider.com

Oppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)

March 1, 2024 | finance.yahoo.com

PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results

March 1, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)

February 29, 2024 | globenewswire.com

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

February 26, 2024 | finance.yahoo.com

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

January 19, 2024 | finanznachrichten.de

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

January 18, 2024 | marketwatch.com

PMV Phamra to Prioritize PC14586 Clinical Development, Will Cut Staff by 30%

January 18, 2024 | msn.com

PMV to focus on lead drug, slashes workforce by 30%

January 18, 2024 | finance.yahoo.com

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

January 5, 2024 | msn.com

PMV Pharmaceuticals names Michael Carulli as CFO

January 5, 2024 | finance.yahoo.com

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

December 28, 2023 | msn.com

Ladenburg Thalmann starts PMV Pharmaceuticals at buy

December 28, 2023 | benzinga.com

PMV Pharma Stock (NASDAQ:PMVP), Analyst Ratings, Price Targets, Predictions

December 27, 2023 | benzinga.com

PMV Pharma Stock (NASDAQ:PMVP), Short Interest Report

December 27, 2023 | msn.com

Ladenburg Thalmann Initiates Coverage of PMV Pharmaceuticals (PMVP) with Buy Recommendation

December 27, 2023 | msn.com

2 Red-Hot Stocks Highlight Wednesday's Top Wall Street Upgrades and Downgrades

December 27, 2023 | finance.yahoo.com

Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

See More Headlines

Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PMVP
CUSIP: N/A
CIK: 1699382
Web: www.pmvpharma.com
Phone: 609-642-6670
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $7.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +254.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.27%
Return on Assets: -27.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.78
Quick Ratio: 14.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.41 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 51,440,000
Free Float: 47,533,000
Market Cap: $82.30 million
Optionable: Optionable
Beta: 1.65

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. David H. Mack Ph.D. (Age 62)
Co-Founder, CEO, President & Director
Comp: $762.02k
Dr. Arnold J. Levine Ph.D. (Age 84)
Co-Founder, Director & Member of Scientific Advisory Board
Comp: $140k
Dr. Thomas E. Shenk Ph.D. (Age 77)
Co-Founder & Member of Scientific Advisory Board
Mr. Michael Carulli
Chief Financial Officer
Mr. Robert Ticktin (Age 62)
General Counsel, Head of Operations & Company Secretary
Mr. Tim Smith
Senior VP & Head of Corporate Development and Investor Relations
Ms. Crystal Zuckerman
Vice President of Human Resources
Dr. Binh Vu Ph.D.
Senior VP of Drug Discovery & CMC
Dr. Deepika Jalota Pharm.D. (Age 47)
Chief Development Officer
Comp: $579.96k
Dr. Marc Fellous M.D.
Senior VP and Head of Clinical Development & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PMVP Stock Analysis - Frequently Asked Questions

Should I buy or sell PMV Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMVP shares.
View PMVP analyst ratings or view top-rated stocks.
What is PMV Pharmaceuticals' stock price target for 2024?: 3 brokerages have issued 12-month price targets for PMV Pharmaceuticals' shares. Their PMVP share price targets range from $5.00 to $7.00. On average, they anticipate the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 252.0% from the stock's current price.
View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts.
How have PMVP shares performed in 2024?: PMV Pharmaceuticals' stock was trading at $3.10 at the beginning of the year. Since then, PMVP shares have decreased by 48.1% and is now trading at $1.61.
View the best growth stocks for 2024 here.
When is PMV Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PMVP earnings forecast.
How were PMV Pharmaceuticals' earnings last quarter?: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its earnings results on Thursday, February, 29th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08.

What ETF holds PMV Pharmaceuticals' stock?: IQ Chaikin U.S. Small Cap ETF holds 85,735 shares of PMVP stock, representing 0.26% of its portfolio.
What other stocks do shareholders of PMV Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).
When did PMV Pharmaceuticals IPO?: PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO.
How do I buy shares of PMV Pharmaceuticals?: Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMVP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial